Compare European CDMOs with EMA-compliant facilities across Germany, Switzerland, Ireland, and the broader EU. Filter by specialization, scale, and regulatory approvals.
926 companies listed
Europe is the second-largest pharma manufacturing region globally, with particular strengths in biologics, API synthesis, and sterile manufacturing. Germany leads in both volume and technological capability, followed by Switzerland (home to major CDMO headquarters), Ireland (a biologics manufacturing hub driven by favorable tax policy), and Italy (strong in API and generics).
EMA regulation provides mutual recognition advantages. A GMP certificate from one EU member state is recognized across the bloc, simplifying multi-market filings. The EMA also maintains Mutual Recognition Agreements (MRAs) with regulators in the US, Canada, Australia, Japan, and other markets, meaning European GMP inspections are often accepted by foreign authorities.
How does pricing compare? European CDMOs typically cost 10-30% more than Asian alternatives but offer shorter lead times for European and US sponsors, stronger IP protection, and established regulatory relationships. For high-value biologics and specialty products, the total cost of quality often favors European manufacturing.
Every country below has its own page with a ranked CDMO list, a country-zoomed facilities map, and the local regulatory picture. Counts are live manufacturing-site totals.
Germany
Vetter Pharma is a leading global Contract Development and Manufacturing Organization specializing in aseptic fill-and-finish services for injectable drug products. Headquartered in Ravensburg, Germany, Vetter operates as an independent, family-owned business with over 75 years of experience.
Germany
BioSpring GmbH is a Frankfurt-based oligonucleotide CDMO and global leader in nucleic acid manufacturing and analysis since 1997. The company specializes in manufacturing mRNA, siRNA, guide RNA, ASO, and other oligonucleotides across all clinical phases to commercial scale. BioSpring has invested over 100 million euros in a new large-scale production facility for nucleic acid-based therapeutics.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.